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Abstract
Introduction: It is unknown whether HIV treatment guidelines, based on resource-rich country cohorts, are applicable to
African populations.
Methods: We estimated CD4 cell loss in ART-naı¨ve, AIDS-free individuals using mixed models allowing for random intercept
and slope, and time from seroconversion to clinical AIDS, death and antiretroviral therapy (ART) initiation by survival
methods. Using CASCADE data from 20 European and 3 sub-Saharan African (SSA) cohorts of heterosexually-infected
individuals, aged $15 years, infected $2000, we compared estimates between non-African Europeans, Africans in Europe,
and Africans in SSA.
Results: Of 1,959 (913 non-Africans, 302 Europeans - African origin, 744 SSA), two-thirds were female; median age at seroconversion
was 31 years. Individuals in SSA progressed faster to clinical AIDS but not to death or non-TB AIDS. They also initiated ART later than
Europeans and at lower CD4 cell counts. In adjusted models, Africans (especially from Europe) had lower CD4 counts at
seroconversion and slower CD4 decline than non-African Europeans. Median (95% CI) CD4 count at seroconversion for a 15–29 year
old woman was 607 (588–627) (non-African European), 469 (442–497) (European - African origin) and 570 (551–589) (SSA) cells/mL
with respective CD4 decline during the first 4 years of 259 (228–289), 155 (110–200), and 199 (174–224) cells/mL (p,0.01).
Discussion: Despite differences in CD4 cell count evolution, death and non-TB AIDS rates were similar across study groups.
It is therefore prudent to apply current ART guidelines from resource-rich countries to African populations.
Citation: Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, et al. (2012) Differences in HIV Natural History among African and Non-African
Seroconverters in Europe and Seroconverters in Sub-Saharan Africa. PLoS ONE 7(3): e32369. doi:10.1371/journal.pone.0032369
Editor: Robert J. Wilkinson, Institute of Infectious Diseases and Molecular Medicine, South Africa
Received October 30, 2011; Accepted January 26, 2012; Published March 6, 2012
Copyright:  2012 Pantazis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under
EuroCoord grant agreement nu 260694. This work was also supported by funding from the Fogarty AIDS International Training and Research Program (AITRP) FIC
2D43 TW001042. This study is made possible by the generous support of the American people through the United States Agency for International Development
(USAID). The contents are the responsibility of the International AIDS Vaccine Initiative and do not necessarily reflect the views of USAID or the United States
Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: npantaz@med.uoa.gr
" Membership of the CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group is provided in the Acknowledgments.
Introduction
HIV disease progression is characterized by CD4 cell depletion
leading to severe immunodeficiency and death in the absence of
effective treatment [1,2]. CD4 cell count, along with plasma HIV-
RNA have been established as the most important prognostic
markers of HIV-1 disease progression [3,4,5] and, as such, are
used to guide therapeutic decisions [6].
Current treatment guidelines are largely based on data from
high-income countries, although the vast majority of the world’s
HIV-infected people live in low and middle-income countries,
particularly sub-Saharan Africa (SSA) [7]. A limited number of
studies have estimated CD4 cell loss in ART-naı¨ve individuals in
African countries [8,9,10], and a few have directly compared this
to estimates derived from high-income countries [11,12,13,14].
Fewer still have used data from individuals with well-estimated
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dates of HIV seroconversion [12,14]. This is important as
measures of CD4 cell count from seroprevalent HIV cohorts do
not capture duration of HIV infection sufficiently [15]. Further-
more, no study has directly compared time from HIV serocon-
version to treatment initiation, clinical AIDS (i.e. not including
CD4,200 cells//mL) [16], or death in SSA and high-income
countries. It remains crucial to understand whether any observed
differences in the rate of CD4 cell decline between population
groups leads to appreciable survival differences. Such differences
would need to be considered when developing guidelines on the
optimal timing of treatment initiation. In addition, understanding
population-specific differences in CD4 cell levels and dynamics
after seroconversion could guide study designs in evaluating multi-
national HIV prevention and vaccine efficacy trial endpoints.
The objectives of this study are to assess and compare CD4 cell
trends, from the time of HIV seroconversion, but prior to
antiretroviral treatment initiation, and time to clinical AIDS or
death, in persons followed in SSA and European cohorts. We also
compare differences in CD4 cell decline and time-to-events
between Africans living in Europe with those living in Africa.
Individuals in the former group were likely infected in Europe as
they had a previous negative HIV test documented in a European
clinic.
Methods
Ethics Statement
All collaborating cohorts received approval from their respective
or national ethics review boards. Ethics approval for CASCADE
collaborating cohorts has been granted by the following commit-
tees: Austrian HIV Cohort Study: Ethik-Kommission der
Medizinischen Universita¨t Wien, Medizinische Universita¨t Graz
– Ethikkommission, Ethikkommission der Medizinischen Univer-
sita¨t Innsbruck, Ethikkommission des Landes Obero¨sterreich,
Ethikkommission fu¨r das Bundesland Salzburg; PHAEDRA
cohort: St Vincent’s Hospital, Human Research Ethics Commit-
tee; Southern Alberta Clinic Cohort: Conjoint Health Research
Ethics Board of the Faculties of Medicine, Nursing and
Kinesiology, University of Calgary; Aquitaine Cohort: Commis-
sion Nationale de l’Informatique et des Liberte´s; French Hospital
Database: Commission nationale de l’informatique et des liberte´s
CNIL; French ANRS PRIMO Cohort: Comite´ Consultatif de
Protection des Personnes dans la Recherche Biome´dicale; French
ANRS SEROCO Cohort: Commission Nationale de l’Informa-
tique et des Liberte´s (CNIL); German HIV-1 Seroconverter Study:
Charite´, University Medicine Berlin; AMACS: Bioethics &
Deontology Committee of Athens University Medical School
and the National Organization of Medicines; Greek Haemophilia
Cohort: Bioethics & Deontology Committee of Athens University
Medical School and the National Organization of Medicines;
ICoNA cohort: San Paolo Hospital Ethic Committee; Italian
Seroconversion Study: Comitato etico dell’Istituto Superiore di
Sanita`; Amsterdam Cohort Studies in Homosexual Men and
IDUs: Academic Medical Centre, University of Amsterdam; Oslo
and Ulleval Hospital Cohorts: Regional komite for medisinsk
forskningsetikk - Øst- Norge (REK 1); Badalona IDU Hospital
Cohort: Comite´ E´tico de Investigacio´n Clı´nica del Hospital
Universitari Germans Trias i Pujol; CoRIS-scv: Comite´ E´tico de
Investigacio´n Clı´nica de La Rioja; Madrid Cohort: Ethics
Committee of Universidad Miguel Hernandez de Elche; Valencia
IDU Cohort: Comite´ Etico de Investigacio´n Clı´nica del Hospital
Dr. Peset-Valencia; Swiss HIV Cohort Study: Kantonale Ethik-
kommission, spezialisierte Unterkommission Innere Medizin,
Ethikkommission beider Basel, Kantonale Ethikkommission Bern,
Comite´ de´partemental d’e´thique de me´decine et me´decine
communautaire, Commission d’e´thique de la recherche clinique,
Universite´ de Lausanne, Comitato etico cantonale, Ethikkommis-
sion des Kantons St.Gallen; UK Register of HIV Seroconverters:
South Birmigham REC; Early Infection Cohorts: Kenya Medical
Research Institute, Kenyatta National Hospital, Uganda Virus
Research Institute Science and Ethics Committee, Uganda
National Council for Science and Technology, Uganda Virus
Research Institute Science and Ethics Committee, Uganda
National Council for Science and Technology, University of
Zambia Research Ethics Committee, Emory IRB, National Ethics
Committee of Rwanda, University of Cape Town Research Ethics
Committee, University of KwaZulu-Natal Nelson R Mandela
School of Medicine; Genital Shedding Study Cohort: University
Hospitals of Cleveland, IRB for Human Investigation (CWRU),
AIDS Research Committee (ARC), STD/AIDS Control Pro-
gramme, Uganda Ministry of Health, Committee on Human
Research (CHR), Office of Research Administration (UCSF),
Biomedical Research & Training Institute (BRTI) – Zimbabwe,
Institutional Review Office, Fred Hutchinson Cancer Research
Center, Medical Research Council of Zimbabwe (MRCZ).
Written informed consent was obtained from all participants.
Minors are not included.
Patients
We used data from the CASCADE Collaboration (Concerted
Action of Seroconversion to AIDS and Death in Europe) in
EuroCoord (www.EuroCoord.net) and the ANRS 1220 PRIMO-
CI study. CASCADE is a collaboration of 25 cohorts of
individuals with well-estimated dates of HIV seroconversion
(seroconverters) [17]; PRIMO-CI is an ongoing prospective
cohort of HIV-1 seroconverters initiated in June 1997 in Abidjan,
Coˆte d’Ivoire [18]. At the time of data update in September 2009
CASCADE included 20 European, 2 Australian and one
Canadian cohort. Two SSA cohorts have also joined CASCADE:
the International AIDS Vaccine Initiative (IAVI)-sponsored
African HIV Research Network Early HIV Infection Cohort
(Kenya, Uganda, Rwanda, Zambia, South Africa) [19] and the
FHI-sponsored Hormonal Contraception (HC) and HIV Genital
Shedding and Disease Progression (GS) Cohort in Uganda and
Zimbabwe [20,21]. Data from the Canadian and Australian
CASCADE cohorts were excluded from this analysis.
The seroconversion date is estimated by various methods: most
frequently as the midpoint between the last documented negative
and first positive HIV antibody test dates with an interval of less
than 3 years between tests, through laboratory evidence of
seroconversion (PCR positivity in the absence of HIV antibodies
or antigen positivity with fewer than four bands on Western blot),
or as the date of a seroconversion illness with both an earlier
documented negative and a later positive HIV test not more than
3 years apart.
Given that the vast majority of individuals recruited in the SSA
cohorts were infected heterosexually and seroconverted in or after
the year 2000, individuals infected through other modes of
transmission or before year 2000 were excluded from current
analyses. Since patterns of change in CD4 count may differ for
children, individuals aged less than 15 years at seroconversion
were also excluded. Finally, we excluded all CD4 cell measure-
ments taken after combination antiretroviral therapy (cART)
initiation or clinical AIDS development and used data only from
individuals with at least two eligible CD4 cell measurements.
cART was defined as either a protease inhibitor-based or a non-
nucleoside reverse transcriptase inhibitor-based regimen, in
combination with at least two nucleoside or nucleotide reverse
HIV Natural History in Europe and Africa
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transcriptase inhibitors (NRTIs), or a triple NRTI regimen.
Women receiving single dose nevirapine for prevention of mother-
to-child HIV transmission were not censored.
Eligible individuals were categorized according to the location
of their cohort (i.e. Europe or SSA). Using information from two
variables collected in CASCADE: ‘‘ethnicity’’ and ‘‘geographic
origin’’, we further divided individuals belonging to European
cohorts. Because limited ethnicity data were collected in the
European cohorts, individuals who were non-white, and whose
country of origin was in SSA or North Africa, were classified as
‘‘Europeans - African origin’’. All other seroconverters in
European cohorts were classified as ‘‘non-African Europeans’’.
Three groups were thus created: non-African Europeans,
Europeans - African origin, and SSAs.
Statistical analysis
CD4 counts at cART initiation and at AIDS diagnosis were
estimated through a modified Kaplan–Meier technique [22]. We
estimated average CD4 cell trends over time, accounting for the
correlation among repeated measurements within each individual,
through linear mixed models with random intercept and random
slope [23]. We used the square root transformation of CD4 count
values to normalise their distribution, stabilise their variance and
linearise changes over time [24].
Using Kaplan-Meier methods, we also estimated times from
HIV seroconversion to each of the following: clinical AIDS,
initiation of cART, death, and loss to follow-up adjusting for late
entry into the cohort. In order to assess whether differences in time
to clinical AIDS were due to pulmonary or extra-pulmonary
tuberculosis (TB), an AIDS-defining event known to occur at
higher rates in African compared to European populations, we
repeated the analysis excluding TB as an AIDS event. Loss to
follow-up was defined as a gap of more than 12 (or 6 in a sensitivity
analysis) months between a patient’s last CD4 evaluation or
clinical assessment and the date their cohort dataset was pooled
within CASCADE.
Sensitivity analyses were performed to investigate the robustness
of our main findings, taking into account the potentially
informative truncation [25,26] of CD4 cell measurements due to
cART initiation or loss to follow-up. More specifically, our final
multivariable mixed model was refitted using joint models for both
the evolution of CD4 cell counts and the time to the potentially
informative event (i.e. cART initiation or loss to follow-up). The
proportion of individuals who progressed to AIDS or died while
ART-naı¨ve was negligible, thus AIDS and death were not
considered as informative censoring events. However, to minimize
the potential bias that may result from those censoring
mechanisms, the analysis was repeated with follow-up censored
at 3 years following seroconversion. Finally, sensitivity analyses
included the application of the main multivariable mixed model
on a dataset where individuals with only one eligible CD4 cell
measurement were included.
All analyses were performed using Stata 10.1 (StataCorp, TX
USA). Joint models were fitted through the Joint Multivariate
Random Effects (JMRE) [26] method using the user-written jmre1
command in Stata [27].
Results
Study population characteristics
The CASCADE database included data from 20,631 individ-
uals: 19,921 from Europe, Australia or Canada, 408 from IAVI-
sponsored cohorts and 302 from FHI-sponsored studies. Data
from a further 285 individuals from the Primo-CI cohort were also
included.
Of the 19,921 individuals from resource-rich countries, we
excluded: 12,910 who had seroconverted before 2000, 4,901 who
were not infected through sex between men and women, 519 who
had one or no CD4 counts while ART-naı¨ve and AIDS-free, 374
who were from non-European cohorts, and 2 who were aged ,15
years. From the 995 individuals in the three SSA cohorts, we
excluded 251 individuals: 105 had seroconverted pre-2000, 94
were not infected through sex between men and women, and 52
had one or no CD4 counts while ART-naı¨ve and AIDS-free. In
summary, the three study groups in these analyses comprising
1,959 individuals were: non-African Europeans (N = 913), Euro-
peans - African origin (N = 302), and SSAs (N = 744).
Of the 1,959 individuals in the final analysis, two-thirds were
female; the median age at seroconversion was 31 years (Table 1).
The median (IQR) duration of follow-up was 3.5 years (1.8–5.7),
representing a total of 7,420 person-years (Table 2). The median
number of CD4 measurements was seven and was higher in SSAs
(10) than in the non-African Europeans (5) and Europeans -
African origin (4).
CD4 cell count evolution
Both the unadjusted and adjusted models estimate lower initial
CD4 cell count as well as slower rates of decline for all Africans
compared to their non-African European counterparts (Table 3).
Differences between the unadjusted and adjusted model were
small with the group effects on the rate of CD4 cell decline being
slightly attenuated in the adjusted models.
Women had consistently higher CD4 cell counts. Younger
individuals and those with a delayed cohort entry of more than 6
months had a slower CD4 cell decline. Calendar year of
seroconversion, method of seroconversion determination, and
interval between last negative and first positive HIV tests dates
were not significantly associated with CD4 cell decline, after
adjusting for other factors included in the multivariable model.
The mean (95% C.I.) estimated CD4 cell count at seroconver-
sion for women, aged 15–29 years who enrolled into the cohorts
within 6 months of seroconversion were 607 (588, 627), 469 (442,
497) and 570 (551, 589) cells/mL for non-African Europeans,
Europeans - African origin, and SSA cohorts, respectively
(Figure 1). The corresponding CD4 cell loss in the first 4 years
from seroconversion was 259 (228, 289), 155 (110, 200) and 199
(174, 224) cells/mL, respectively.
AIDS diagnoses, survival, cART initiation and loss to
follow-up
Despite the slower rate of CD4 cell loss, the probability of being
diagnosed with clinical AIDS was higher in all Africans,
particularly in SSA cohorts (Figure 2). The most common clinical
AIDS events in SSA cohorts were pulmonary TB (29.7%) and
HIV wasting syndrome (14.9%). The corresponding events in
Europe were Pneumocystis pneumonia (20.0%) and Kaposi
Sarcoma (17.1%) among persons of non-African origin; TB was
the most common first AIDS-defining event (61.6%) among
Europeans of Africa origin (extra-pulmonary (38.5%) and
pulmonary (23.1%)). After excluding pulmonary or extra-pulmo-
nary TB as an AIDS event, however, we found only a marginal
difference in time to clinical AIDS between the three groups
(p = 0.06). Overall survival including persons with TB was similar,
however, among the three study groups.
Individuals in SSA cohorts tended to initiate treatment later
than those in the European cohorts (p,0.001). Estimated median
(95% CI) CD4 cell count at cART initiation was 296 (287, 309),
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274 (262, 290) and 188 (172, 192) cells/mL for non-African
Europeans, Europeans of African origin, and SSAs, respectively
(p,0.001). The corresponding estimated median (95% CI) CD4
cell count at AIDS diagnosis was 42 (19, 116), 143 (,52, 164) and
82 (22, 126) cells/mL (p = 0.078).
Rates of loss to follow-up (among AIDS-free persons not on
cART) were substantially higher in European cohorts compared to
SSA cohorts (Figure 2) (p,0.001).
Sensitivity analyses
Sensitivity analyses showed that our results were robust when
taking into account the potentially informative truncation of CD4
cell measurements due to loss to follow-up. When we simulta-
neously fitted the final multivariable model for CD4 cell evolution
(Table 3) with a survival model for the time to loss to follow-up, the
changes in the estimates of the CD4 cell count model were
negligible irrespectively of the loss to follow-up definition (i.e. $12
or $6 months gap).
We adjusted for potentially informative truncation of CD4 cell
count measurements due to cART initiation. This resulted in a
much faster decline in CD4 count, but the average CD4 cell count
at seroconversion and the corresponding differences between
groups remained similar to those in the main analysis. The
corresponding difference between individuals in SSA and non-
African Europeans became more pronounced and was highly
significant; the difference in slopes between non-African Europe-
ans and Europeans - African origin became attenuated and was no
longer significant. However, treating cART as an informative
censoring event is probably inappropriate in this case since
decisions about its initiation are mainly based on already observed
outcomes (i.e. prior CD4 cell measurements). Moreover, the
application of the mixed models in our main analysis on data
Table 1. Demographic and clinical characteristics of 1959 seroconverters from European and sub-Saharan African (SSA) cohorts.
Group
Europe (non-African
origin) N=913
Europe (African
origin) N=302 SSA N=744 Overall N=1,959 P
Sex ,0.001
Male 375 (41.1) 87 (28.8) 237 (31.9) 699 (35.7)
Female 538 (58.9) 215 (71.2) 507 (68.1) 1260 (64.3)
Median (IQR) age at SC (years) 34 (26, 44) 29 (25, 35) 29 (24, 34) 31 (25, 38) ,0.001
Ethnic group ,0.001
White 243 (26.6) 0 (0.0) 0 (0.0) 243 (12.4)
Black 53 (5.8) 39 (12.9) 744 (100.0) 836 (42.7)
Other 9 (1.0) 0 (0.0) 0 (0.0) 9 (0.5)
Unknown 608 (66.6) 263 (87.1) 0 (0.0) 871 (44.5)
Initiated cART 483 (52.9) 181 (59.9) 167 (22.4) 831 (42.4) ,0.001
Developed AIDS 32 (3.5) 13 (4.3) 58 (7.8) 103 (5.3) 0.002
Died 15 (1.6) 3 (1.0) 23 (3.1) 41 (2.1) 0.177
Year of SC ,0.001
2000–03 560 (61.3) 170 (56.3) 314 (42.2) 1044 (53.3)
2004+ 353 (38.7) 132 (43.7) 430 (57.8) 915 (46.7)
Method of SC determination 0.001
Midpoint 785 (86.0) 263 (87.1) 683 (91.8) 1731 (88.4)
Lab. evidence 121 (13.3) 36 (11.9) 61 (8.2) 218 (11.1)
SC illness 7 (0.8) 3 (1.0) 0 (0.0) 10 (0.5)
Subtype ,0.001
A 14 (1.5) 1 (0.3) 156 (21.0) 171 (8.7)
B 81 (8.9) 2 (0.7) 2 (0.3) 85 (4.3)
C 26 (2.8) 1 (0.3) 312 (41.9) 339 (17.3)
CRF01 12 (1.3) 0 (0.0) 0 (0.0) 12 (0.6)
CRF02 22 (2.4) 29 (9.6) 67 (9.0) 118 (6.0)
Other 10 (1.1) 9 (3.0) 93 (12.5) 112 (5.7)
Unknown 748 (81.9) 260 (86.1) 114 (15.3) 1122 (57.3)
Median (IQR) time (months) 5.8 7.2 3.7 5.2 ,0.001
between SC and enrolment (2.1, 10.9) (3.6, 12.0) (0.6, 7.8) (2.0, 10.0)
Median (IQR) time (months) 10.7 14.0 2.9 6.6 ,0.001
between last HIV2 and HIV+ test* (5.2, 19.0) (8.2, 22.0) (1.4, 4.2) (2.9, 15.0)
Numbers and percentage of respective populations given unless otherwise indicated;
*Only for those with a ‘‘Midpoint’’ method of SC determination; IQR: Interquartile Range; SC: Seroconversion.
doi:10.1371/journal.pone.0032369.t001
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Table 2. Available CD4 cell measurements, frequency and follow-up time of 1959 seroconverters from European and sub-Saharan
African (SSA) cohorts.
Group
Europe (non-African
origin)
Europe (African
origin) SSA Overall
Median (IQR) Median (IQR) Median (IQR) Median (IQR) P-value
Time from seroconversion to first CD4 cell
measurement (months)
6.1 (2.7, 11.2) 7.4 (3.6, 12.1) 3.7 (0.6, 7.8) 5.3 (2.4, 10.1) ,0.001
Time from seroconversion to last available CD4 cell
measurement (years)
3.5 (2.1, 5.2) 3.4 (2.0, 5.1) 3.5 (1.6, 6.3) 3.5 (1.8, 5.7) 0.566
Time from seroconversion to last CD4 cell
measurement after applying truncation* (years)
2.1 (1.1, 3.5) 1.6 (1.0, 3.1) 2.9 (1.4, 5.4) 2.3 (1.2, 4.0) ,0.001
Interval between consecutive CD4 cell
measurements (months)
3.2 (2.3, 4.6) 2.9 (1.6, 4.4) 2.9 (2.4, 3.9) 3.0 (2.3, 4.4) 0.001
Number of CD4 cell measurements 5 (3, 9) 4 (2, 8) 10 (6, 15) 7 (3, 11) ,0.001
*CD4 cell measurements after cART initiation or AIDS onset were truncated for this analysis; IQR: Interquartile Range.
doi:10.1371/journal.pone.0032369.t002
Table 3. Estimates from fitting a univariate (unadjusted) and a multivariable (adjusted) linear mixed model on all repeated
measurements of CD4 cell counts (square root transformed) taken from seroconversion to end of follow-up, cART initiation or
clinical AIDS onset.
Unadjusted Adjusted
Covariate Coef.1 95% C.I. p-value Coef.1 95% C.I. p-value
CD4 cell count at seroconversion (square root cells/mL)
Reference category2 24.20 (23.85, 24.55) ,0.001 23.53 (23.08, 23.97) ,0.001
Group
Europe (non-African origin)* 0.00 0.00
Europe (African origin) 22.83 (23.55, 22.11) ,0.001 22.97 (23.69, 22.25) ,0.001
SSA 20.68 (21.20, 20.17) 0.009 20.76 (21.28, 20.25) 0.004
Sex
Male* — — — 0.00
Female — — — 1.11 (0.65, 1.57) ,0.001
CD4 cell rate of decline (square root cells/mL per year)
Reference category3 21.56 (21.69, 21.42) ,0.001 21.49 (21.69, 21.30) ,0.001
Group
Europe (non-African origin)* 0.00 0.00
Europe (African origin) 0.62 (0.32, 0.92) ,0.001 0.51 (0.21, 0.81) 0.001
SSA 0.44 (0.25, 0.62) ,0.001 0.34 (0.15, 0.54) 0.001
Age at seroconversion (years)
15–29* — — — 0.00
30–39 — — — 20.10 (20.29, 0.08) 0.284
40–49 — — — 20.34 (20.62, 20.06) 0.016
50+ — — — 20.63 (20.97, 20.30) ,0.001
Enrolment time (months)
#6* — — —
.6 — — — 0.22 (0.05, 0.38) 0.010
*Baseline category;
1: Coefficients denote either mean estimated value for the reference category or mean estimated differences relative to the baseline category;
2: Men of non-African origin in European cohorts;
3: Individuals of non-African origin in European cohorts, aged 15–29 years at seroconversion and with a #6 months gap between seroconversion and study entry.
doi:10.1371/journal.pone.0032369.t003
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Figure 1. Predicted average CD4 cell count evolution by study group (women, aged 15–29 years at seroconversion, enrolled into
cohorts within 6 months of seroconversion).
doi:10.1371/journal.pone.0032369.g001
Figure 2. Kaplan-Meier curves of the cumulative probability of a) clinical AIDS, b) clinical AIDS (excluding TB cases) c) Death, d)
cART initiation and e) loss to follow-up ($12 months) before cART initiation or AIDS onset. Curves shown by study group: individuals of
non-African origin (solid line) or of African origin (dotted line) in European cohorts and individuals in SSA cohorts (dashed line).
doi:10.1371/journal.pone.0032369.g002
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where we artificially censored follow-up at 3 years after
seroconversion, yielded very similar estimates to those reported
in Table 3.
Finally, when we included data from the 469 individuals with
only one CD4 cell count while ART-naı¨ve and AIDS-free, our
main findings remained practically unchanged. The sole exception
was that the difference in initial CD4 cell count between
individuals in SSA and non-African Europeans was attenuated
and no longer statistically significant. The majority of the
additional individuals were in the latter group and started cART
immediately after their first CD4 cell measurement.
Discussion
We found that Africans, particularly those in European cohorts,
have lower initial CD4 cell counts and slower rates of CD4 cell
decline in the absence of cART. This does not, however, appear to
have conferred them with any survival advantage. That said,
because we had limited duration of follow-up (median, 3.5 years),
there may be inherent differences in long-term survival that we
were unable to detect.
Although seroconverters in SSA were initially seemingly
disadvantaged by having lower CD4 cell counts at seroconversion,
their subsequent slower CD4 cell loss resulted in them reaching the
same CD4 levels as the other two groups by approximately 2.5
years after seroconversion. Their average CD4 count was higher
thereafter falling below 350 cells/mL almost 6 months later than
that of non-African Europeans. In contrast, Europeans - African
origin consistently had the lowest average CD4 counts throughout
the follow-up period and reached a CD4 count of350 cells/mL
approximately 1 to 1.5 years earlier than non-African Europeans
and Africans living in SSA, respectively. Of note, the slower CD4
cell count decline in African populations remained evident even
after conditioning on CD4 levels at seroconversion.
These findings are in agreement with two smaller seroconverter
cohorts with shorter follow-up time [12,14] and a number of
seroprevalent cohorts, of lower CD4 cell counts and similar or
milder CD4 cell decline in Africans compared to their counter-
parts in Europe and North America [11,13,28,29,30].
It is well known that, even in healthy individuals, lymphocyte
subset values are influenced by various factors including genetics
and the environment [31]. Genetic factors such as HLA type can
segregate along African tribal lines. In sub-Saharan Africa
environmental factors such as parasitic (e.g. malaria, schistosomi-
asis), respiratory, and gastrointestinal co-morbidities are much
more common than in Europe and will likely affect the immune
status of residents. Furthermore, it has been proposed that the
infecting HIV-1 subtype may also influence CD4 levels [13].
Given that subtype information was unavailable for more than
80% of individuals from Europeans cohorts and, for those with
known subtype, the most prevalent subtype among non-African
Europeans was B (49%) and, among Africans, non-B (69%
CRF_02 and 74% A or C for Europeans- African origin and SSA,
respectively) with only 2 SSA seroconverters being infected with
subtype B, we were not able to assess the contribution of subtype,
in addition to that of ethnicity and geographic origin. A large CD4
difference between Africans and non-Africans followed in the
French ANRS PRIMO cohort was found after controlling for
subtype [32]. Muller et al’s study [29] concluded that the
differences they observed in rate of CD4 cell loss among Africans
and Europeans in the Swiss HIV cohort were unlikely to be due to
environmental factors, since they were all located in Switzerland,
or to the infecting HIV-1 subtype, since differences persisted even
after controlling for subtype. Their conclusion that these
differences were likely due to host genetic factors is further
supported by our findings of a slower rate of CD4 cell loss
experienced by Africans, in both the European and SSA cohorts
compared to non-African Europeans. Environmental factors may
still play a role, however, since adaptation to a new environment
after relocation takes place gradually over time. Unfortunately, we
do not have data on dates of migration to Europe for the
Europeans of African origin to allow further exploration. Of note,
however, we found that CD4 levels for Europeans- African origin
were much lower than those in the SSA cohorts. One reason for
this is that African populations are genetically very diverse, and
large differences in CD4 levels (both pre- and post-seroconversion)
have been observed even among populations living in geograph-
ically-close countries [33]. In our study, the majority of the
Europeans of African origin live in France and are more likely to
originate from North and West Africa rather than from Eastern or
Southern Africa, where the majority of the participants in the SSA
cohorts originate.
Africans, particularly those in SSA cohorts, progressed to
clinical AIDS significantly faster than non-African Europeans
(p = 0.002). After excluding both pulmonary and disseminated TB
as AIDS-defining events, however, we found little evidence of a
difference in time to AIDS between groups (p = 0.06). We
acknowledge that the power of this comparison is reduced due
to the low number of non-TB AIDS events. However, this suggests
that the difference between the Europeans and Africans in
European cohorts is largely due to differences in TB rates. This
TB rate differential partially, accounts for the differences in
progression to AIDS between the SSA and both European groups
as well. Any remaining difference in time to AIDS may be due to
differences in co-infection rates and existing co-morbidities. For
example, malaria is reported to facilitate HIV replication through
increased cytokine production and immune cell activation [34]
leading to CD4 cell loss and the consequent diagnosis of AIDS-
defining conditions. Residual differences in progression to AIDS
may also be an artefact of the higher number of CD4 cell
measurements taken from SSA cohort participants compared to
participants in the resource-rich country cohorts (10 vs. 5 and 4
measurements, respectively). The more frequent CD4 testing
would allow an AIDS diagnosis to be made earlier. The fact that
TB is often diagnosed at higher CD4 cell counts [35] may also
explain why the SSA group (which had higher TB rates)
progressed to AIDS more rapidly despite their slower CD4 cell
decline.
Not surprisingly, given the differences in HIV treatment
guidelines based on CD4 counts and the tendency in Europe to
treat primary HIV infection, we found that individuals in
European cohorts initiated cART earlier than their SSA
counterparts. Individuals in SSA cohorts initiated cART with
86–108 CD4 cells/mL, on average, lower than their counterparts
in European cohorts. Despite lower CD4 cell count at cART
initiation, after TB is excluded as an AIDS-defining event,
estimated time to clinical AIDS for individuals from SSA cohorts
is similar to that of Europeans. This suggests that the slower CD4
cell loss may have conferred a clinical benefit counterbalancing
lower CD4 counts at seroconversion. It also supports the WHO
recommendations for active TB case finding and isoniazid
preventive therapy for HIV-infected individuals in Africa [36] to
improve clinical prognosis.
Europeans - African origin in this analysis were more likely to
initiate cART soon after seroconversion compared to non-African
Europeans. This is, most probably, because the majority of
identified Africans (n = 288, 95%) in European cohorts were
enrolled in France, a country with particular interest in treating
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primary HIV infection [37]; French cohorts of African and non-
African ancestry comprised 48% of the data in our analyses.
Interestingly, individuals enrolled into cohorts within 6 months
of seroconversion had significantly faster rates of CD4 cell decline
compared to those enrolled later. This suggests that, in cohorts
with substantial delayed enrolment, there may exist a preferential
inclusion of slow progressors because those progressing more
rapidly are less likely to be enrolled into cohorts. It may also be
because the rate of CD4 loss is higher around the time of
seroconversion, and this rapid drop is more likely to be identified
in individuals with shorter enrolment times and more frequent
CD4 cell measurements. Of note, the time from infection to cohort
enrolment was longer in the European, compared to the SSA
cohorts, particularly for individuals of African origin. Even after
adjusting for this, however, we found significantly slower CD4 cell
loss among Europeans - African origin. Moreover, restricting the
analysis to those with short (i.e. ,6 or ,3 months) enrolment
delay did not alter significantly our main findings.
These results were based on the analysis of longitudinal data
derived from a large collaboration of prospective cohorts in 7 West
European and 7 SSA countries. The large size of the CASCADE
database allowed us to restrict the analysis to recent seroconverters
and to those heterosexually infected. Importantly, the robustness
of our findings regarding the effects of the most common
truncation mechanisms and the exclusion of individuals with only
one CD4 measurement while ART-naı¨ve and AIDS-free has been
investigated through a series of sensitivity analyses. Results from
these analyses showed that our findings regarding the lower initial
CD4 cell count levels of African immigrants in Europe and the
slower rate of CD4 cell loss among SSA seroconverters remained
consistent with those of the main analysis.
Our study is based on data from observational cohorts. Despite
restricting the European data to include only individuals with the
characteristics of African cohorts and adjusting for most of the
known prognostic and confounding factors, residual confounding
and potential selection bias in cohort enrolment cannot be ruled
out. Because the healthcare infrastructure in SSA is limited and
quality healthcare difficult to access, the frequent study visits, and
resulting increased contact with clinicians, experienced by the SSA
cohorts could also influence the health status and outcomes for the
SSA cohorts. These factors most likely contributed to the low loss
to follow-up rate seen in the SSA cohorts as well. The SSA cohorts
provided transportation and/or reimbursement for transportation
and time, health care services for acute illnesses, regular
counselling, active follow-up of individuals who missed study visits
and required frequent study visits. All of these are factors effective
in promoting low loss to follow-up rates in resource-poor settings.
Furthermore, seroconverters may not be representative of the
general HIV-infected population, although we recently showed
that estimates of HIV progression derived from seroconverter
cohorts are similar to that seen in the general HIV-infected
population [38].
In conclusion, although Africans in SSA and Europe demon-
strated a slower rate of CD4 cell decline and higher rates of
tuberculosis than non-African Europeans, survival rates and AIDS
rates, excluding TB, were similar. Given that treatment decisions,
particularly in resource-rich countries, are largely based on CD4
levels, understanding initial CD4 counts at seroconversion,
subsequent CD4 decline, and the time from seroconversion to
key CD4 thresholds (e.g. 350, 200 cells/mL) will impact the timing
of ART initiation. Based on these findings, it appears, therefore,
that HIV treatment guidelines developed from cohorts in Europe
are applicable and appropriate for Africans. Universal access and
implementation of such guidelines remains the primary challenge.
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